Within its discussion of strategic growth investments, the company refers to “enhancing commercial capabilities, including expansion of geographic sales reach and e-commerce platforms, marketing initiatives, expanded service and operational infrastructure, and research and development projects,” reflecting efforts to acquire, deploy and reconfigure resources to support and enhance business processes and customer experience. The company describes productivity improvements from its “practical process improvement (PPI) business system including reduced costs resulting from implementing continuous improvement methodologies, global sourcing initiatives, a lower cost structure following restructuring actions, including headcount reductions and consolidation of facilities,” indicating ongoing process optimization and resource mobilization. Additionally, through acquisitions such as Mesa Biotech’s “PCR based rapid point-of-care testing platform,” the European viral vector manufacturing business providing advanced biologics manufacturing services, and PPD’s clinical research services to “accelerate innovation and increase their productivity within the drug development process,” the company highlights its capability to integrate and leverage specialized technology resources and expertise to deliver innovative solutions, scale operations and maintain a competitive market position.